Compare Amgen, Inc. (AMGN) vs iShares Gold Trust (IAU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs iShares Gold Trust — how do they compare? Amgen, Inc. trades at $357.02 (market cap $196.12B), while iShares Gold Trust trades at $75.49. The key difference: Amgen, Inc. pays a 2.77% dividend while iShares Gold Trust pays none, and Amgen, Inc. is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals.
| AMGN | IAU | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $388.16 | $101.57 |
52-Week Low | $271.18 | $61.62 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
IAU is trading at $77.26, down 0.32% with bearish technical signals dominating the short-term outlook. The stock shows mixed momentum with RSI indicators suggesting potential overbought conditions on shorter timeframes while longer-term indicators remain neutral. Recent market sentiment reflects uncertainty around gold prices, with central bank buying providing support but macroeconomic factors creating headwinds.
The stock faces near-term pressure from technical bearish signals and gold market volatility, though institutional accumulation during price weakness suggests long-term confidence. Key risks include Federal Reserve policy decisions and inflation data, while potential upside exists if geopolitical tensions or economic uncertainty drive safe-haven demand for gold-related assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →
